Condition: Acute Myeloid Leukemia · Sponsor: Technische Universität Dresden
This phase I/II clinical trial evaluates the safety and efficacy of the combined administration of midostaurin and gemtuzumab ozogamicin in the frame of first-line standard chemotherapy in newly diagnosed acute myeloid leukemia (AML) patients displaying a cytogenetic aberration or fusion transcript in the core-binding factor (CBF) genes or FMS-like tyrosine Kinase 3 (FLT3) mutation.
This description comes directly from the study's public registry record.
Christoph Röllig, Prof. Dr. · +49 351 458 · MOSAIC@ukdd.de
Manja Reimann, Dr. · +49 351 458 · MOSAIC@ukdd.de
Always discuss trial participation with your own doctor first.
| LMU Klinikum, Campus Großhadern | München, Bavaria, Germany | Recruiting |
| Universitätsklinikum Essen | Essen, North Rhine-Westphalia, Germany | Recruiting |
| Universitätsklinikum Aachen | Aachen, Germany | Recruiting |
| Universitätsklinikum Augsburg | Augsburg, Germany | Not Yet Recruiting |
| Klinikum Chemnitz gGmbH | Chemnitz, Germany | Recruiting |
| Universitätsklinikum Dresden | Dresden, Germany | Recruiting |
| Johann Wolfgang Goethe-Universität | Frankfurt am Main, Germany | Recruiting |
| Universitätsklinikum Halle | Halle, Germany | Recruiting |
| Universitätsklinikum Heidelberg | Heidelberg, Germany | Recruiting |
| Universitätsklinikum Jena | Jena, Germany | Recruiting |
| Universitätsklinikum Schleswig-Holstein | Kiel, Germany | Recruiting |
| Gemeinschaftsklinikum Mittelrhein gGmbH | Koblenz, Germany | Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04385290